Logo

Rosetta Licenses Resolver to COR Therapeutics

Nov 26, 2001

NEW YORK, Nov. 26 - Rosetta Biosoftware announced on Monday that it has licensed its Resolver gene-expression data-analysis system to COR Therapeutics.

 

Rosetta's technology will "help us lay the groundwork for the development of novel pharmaceutical products to treat cardiovascular diseases," said James N. Topper, vice president for biology at South San Francisco, Calif.-based COR Therapeutics.

 

Financial terms of the agreement were not disclosed.

 

The Resolver bioinformatics system is distributed by Rosetta, the Kirkland, Wash.-based Merck business, and Palo Alto, Calif.-based Agilent Technologies.

Breaking News
The Scan

Another Resignation

According to the Wall Street Journal, a third advisory panel member has resigned following the US Food and Drug Administration's approval of an Alzheimer's disease drug.

Novavax Finds Its Vaccine Effective

Reuters reports Novavax's SARS-CoV-2 vaccine is more than 90 percent effective in preventing COVID-19.

Can't Be Used

The US Food and Drug Administration says millions of vaccine doses made at an embattled manufacturing facility cannot be used, the New York Times reports.

PLOS Papers on Frozen Shoulder GWAS, Epstein-Barr Effects on Immune Cell Epigenetics, More

In PLOS this week: genome-wide association study of frozen shoulder, epigenetic patterns of Epstein-Barr-infected B lymphocyte cells, and more.